{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:29Z","timestamp":1791478049333,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clinthera.2016.11.020","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T22:56:01Z","timestamp":1481842561000},"page":"138-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic Interactions Between Pelubiprofen and Eperisone Hydrochloride: A Randomized, Open-label, Crossover Study of Healthy Korean Men"],"prefix":"10.1016","volume":"39","author":[{"given":"Ju-Hee","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Son","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu-Jeong","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyoung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.11.020_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0378-4347(93)80198-D","article-title":"Stereoselective determination of the active metabolites of a new anti-inflammatory agent (CS-670) in human and rat plasma using antibody-mediated extraction and high-performance liquid chromatography","volume":"613","author":"Takasaki","year":"1993","journal-title":"J Chromato"},{"key":"10.1016\/j.clinthera.2016.11.020_bib2","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1002\/jcb.23290","article-title":"Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohewylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-kB inactivation","volume":"112","author":"Shin","year":"2011","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.clinthera.2016.11.020_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1471-2474-15-375","article-title":"Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial","volume":"15","author":"Choi","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2016.11.020_bib4","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1248\/bpb.18.1584","article-title":"Stereospecific taurine conjugation of the trans-OH metabolite (active metabolite) of CS-670, a new 2-arylpropionic acid nonsteroidal anti-inflammatory drug, in dogs","volume":"18","author":"Asami","year":"1995","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2016.11.020_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/BRS.0b013e318166e051","article-title":"The effect of muscle relaxant on the paraspinal muscle blood flow: a randomized controlled trial in patients with chronic low back pain","volume":"33","author":"Sakai","year":"2008","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.clinthera.2016.11.020_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13318-011-0034-0","article-title":"Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry","volume":"36","author":"Melilli","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.11.020_bib7","unstructured":"Myonal\u00ae [prescribing information]. Eisai Co. http:\/\/www.eisai.jp\/medical\/products\/di\/EPI\/MYO_T-G_EPI.pdf. Accessed October 5, 2016."},{"key":"10.1016\/j.clinthera.2016.11.020_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0022-3565(25)24210-0","article-title":"Eperisone, an antispastic agent, possesses vasodilating actions on the guinea-pig basilar artery","volume":"235","author":"Fujioka","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2016.11.020_bib9","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12325-008-0108-9","article-title":"Open experience with a new myorelaxant agent for low back pain","volume":"25","author":"Sartini","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2016.11.020_bib10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.clinthera.2013.08.012","article-title":"Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean men","volume":"35","author":"Kim","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.11.020_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.chroma.2015.02.008","article-title":"Simultaneous determination of eperisone hydrochloride and paracetamol in mouse plasma by high performance liquid chromatography-photodiode array detector","volume":"1388","author":"Locatelli","year":"2015","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.clinthera.2016.11.020_bib12","first-page":"835","article-title":"Studies on the metabolic fate of 4\u2019-ethyl2-methyl-3-piperidinopropiophenone hydrochloride (1): absorption, distribution and excretion in rats and guinea pigs","volume":"21","author":"Fujita","year":"1981","journal-title":"Pharmacometrics"},{"key":"10.1016\/j.clinthera.2016.11.020_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0009-9236(96)90208-8","article-title":"Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies","volume":"60","author":"Hellriegel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.11.020_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00498250802509448","article-title":"Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone","volume":"39","author":"Yoo","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2016.11.020_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2016.11.020_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/chromsci\/42.5.254","article-title":"Rapid and sensitive liquid chromatography-electrospray ionization-mass spectrometry method for the determination of eperisone in human plasma: method and clinical applications","volume":"42","author":"Ding","year":"2004","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.clinthera.2016.11.020_bib17","year":"2001","journal-title":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence"},{"key":"10.1016\/j.clinthera.2016.11.020_bib18","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.clinthera.2016.11.020_bib19","doi-asserted-by":"crossref","unstructured":"Yanni SB. Phase 1-Phase 3 clinical studies, procedures, responsibilities, and documentation. In: Translational ADMET for drug therapy: Principles, methods, and pharmaceutical applications. Hoboken, NJ, USA: John Wiley & Sons Inc. 2015.","DOI":"10.1002\/9781118838440.ch10"},{"key":"10.1016\/j.clinthera.2016.11.020_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jchromb.2014.12.037","article-title":"Development and validation of an LC-MS\/MS method for the determination of pelubiprofen and its active metabolite, trans-alcohol, in human plasma and its application to pharmacokinetic study","volume":"983-984","author":"Ryu","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2016.11.020_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1520-636X(1996)8:2<207::AID-CHIR6>3.0.CO;2-F","article-title":"Disposition of CS-670, a novel nonsteroidal anti-inflammatory drug, and its metabolites in healthy human volunteers","volume":"8","author":"Asami","year":"1996","journal-title":"Chirality"},{"key":"10.1016\/j.clinthera.2016.11.020_bib22","unstructured":"Pelubi (pelubiprofen) [KR prescribing information] http:\/\/ezdrug.kfda.go.kr. Accessed October 5, 2016."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181630858X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181630858X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T17:37:58Z","timestamp":1749836278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181630858X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S014929181630858X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic Interactions Between Pelubiprofen and Eperisone Hydrochloride: A Randomized, Open-label, Crossover Study of Healthy Korean Men","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}